Trillium Therapeutics (TRIL) Reports Dosing of First Patient With TTI-622, a Second Immune Checkpoint Inhibitor Targeting CD47
Tweet Send to a Friend
Trillium Therapeutics Inc. (NASDAQ: TRIL) announced today that it has initiated dosing in its phase 1 clinical trial of TTI-622 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
